TABLE 2.
Tumor Standardized Uptake Values (SUVs) for 18F-FDG, Copper-Diacetyl-Bis(N4-Methylthiosemicarbazone) (62Cu-ATSM), and Copper-Pyruvaldehyde-Bis(N4-Methylthiosemicarbazone) (62Cu-PTSM)
| Characteristic | Patient 1a | Patient 2 a | Patient 3 | Patient 4 a | Patient 5 | Patient 6 | Patient 7b | Patient 8 | Patient 9 | Patient 10 |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Tumor location, size | LUL, 7.11 cm3; RUL, 3.81 cm3 | RLL, 206.8 cm3 | RUL, 5.44 cm3 | RUL, 0.36 cm3 | RUL, 17.71 cm3 | RUL, 2.91 cm3 | ||||
| FDG | ||||||||||
| Maximum SUV | 10.5 | 8.4 | LUL, 12.1; RUL, 17.6 | 15.0 | NAc | 7.1 | 10.1 | 5.5 | 9.1 | LUL, 17.0; RUL, 16.6 |
| Dose (mCi) [MBq] | 10.4 [384.8] | 10.0 [370.0] | 12.3 [455.1] | 16.3 [603.1] | 14.2 [525.4] | 10.0 [370.0] | 13.1 [484.7] | 11.4 [421.8] | 13.5 [499.5] | |
| Time between FDG PET and 62Cu-PET studies | > 30 d | 27 d | 1 h | 5 h | 11 d | 1 h | 2 h | 1 h | 1 h | 1 h |
| 62Cu-PTSM | ||||||||||
| Dose (mCi) [MBq] | 3.76 [139.12] | 8.9 [329.3] | 8.18 [302.66] | 9.75 [360.75] | 13.9 [514.3] | 5.07 [187.59] | 14.29 [528.73] | 12.76 [472.12] | 16.34 [604.58] | 16.01 [592.37] |
| SUV for tumor | 3.63 | 1.73 | 16.1 | 7.5 | 15.9 | 15.9 | 27.1 | 22.4 | 61.1 | 27.8 |
| 62Cu-ATSM | ||||||||||
| Dose (mCi) [MBq] | 6.87 [254.19] | 8.3 [307.1] | 7.55 [279.35] | 9.1 [336.7] | 14.75 [545.75] | 14.54 [537.98] | NA | 13.86 [512.82] | 14.46 [535.02] | 13.62 [503.94] |
| SUV for tumor | 2.71 | 1.00 | 9.8 | 5.1 | 13.2 | 36.6 | NA | 17.2 | 37.3 | 16 |
Note—LUL3= left upper lobe, NA3= not applicable, RLL3= right lower lobe, RUL3= right upper lobe.
a
Patients whose imaging scans were not complete enough to calculate 62Cu-ATSM and 62Cu-PTSM differences.
b
Patient did not complete 62Cu-ATSM imaging.
c
Patient whose PET scan was performed before initial medical evaluation at our hospital, and SUV was not reported.